<code id='F96D398D9A'></code><style id='F96D398D9A'></style>
    • <acronym id='F96D398D9A'></acronym>
      <center id='F96D398D9A'><center id='F96D398D9A'><tfoot id='F96D398D9A'></tfoot></center><abbr id='F96D398D9A'><dir id='F96D398D9A'><tfoot id='F96D398D9A'></tfoot><noframes id='F96D398D9A'>

    • <optgroup id='F96D398D9A'><strike id='F96D398D9A'><sup id='F96D398D9A'></sup></strike><code id='F96D398D9A'></code></optgroup>
        1. <b id='F96D398D9A'><label id='F96D398D9A'><select id='F96D398D9A'><dt id='F96D398D9A'><span id='F96D398D9A'></span></dt></select></label></b><u id='F96D398D9A'></u>
          <i id='F96D398D9A'><strike id='F96D398D9A'><tt id='F96D398D9A'><pre id='F96D398D9A'></pre></tt></strike></i>

          hotspot

          hotspot

          author:leisure time    Page View:66
          UnitedHealth Group
          UnitedHealth Group’s Optum will pay $3.3 billion total for the home health giant Amedisys. Jim Mone/AP

          Home health and hospice chain Amedisys has chosen a new corporate owner.

          Amedisys and UnitedHealth Group’s Optum agreed to a deal Monday in which UnitedHealth will pay $101 per share in cash for Amedisys, totaling $3.3 billion. UnitedHealth’s latest offer is $1 per share higher than what it proposed in its unsolicited buyout offer a few weeks ago.

          advertisement

          Option Care Health, a company that delivers intravenous medicines and mails health care supplies to people’s homes, originally offered to acquire Amedisys in May in an all-stock deal. However, the attractiveness of that deal deteriorated after Option Care’s stock price plummeted soon after the company made its bid.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          Caribou posts encouraging results on off
          Caribou posts encouraging results on off

          RachelHaurwitz,CEOofCaribouBiosciences.ElizabethD.HermanforSTATCaribouBiosciencessaidThursdaythatits

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          Some dementia cases could be undiagnosed liver disease

          AdobeThedescentintodementiacanfeelliketraversingaminefield,comingacrossnewsymptomswithoutthehopeofac